NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice

Peptides

Volumn 31, Issue 4, 2010, Pages 671-675

  Moriya, Ryuichi ^a   Shirakura, Takashi ^a   Hirose, Hiroyasu ^a   Kanno, Tetsuya ^a   Suzuki, Jun ^a   Kanatani, Akio ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Diarrhea; NPY Y2; Peptide YY(3 36)

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; CASTOR OIL; LEUCINE; LOPERAMIDE; NEUROPEPTIDE Y [24-36]; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY [3-36]; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EXPERIMENTAL MODEL; INTESTINE FLUID; INTESTINE FUNCTION; INTESTINE SECRETION; INTESTINE TRANSIT TIME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; ANTIDIARRHEALS; DIARRHEA; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL SECRETIONS; LOPERAMIDE; MALE; MICE; MICE, INBRED C57BL; PEPTIDE YY; RECEPTORS, NEUROPEPTIDE Y;

MUS;

EID: 77649233300     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.11.005     Document Type: Article

References (35)

1. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
2. Bennett A. Cholera and prostaglandins. Nature 231 (1971) 536
3. Beubler E., Bukhave K., and Rask-Madsen J. Significance of calcium for the prostaglandin E2-mediated secretory response to 5-hydroxytryptamine in the small intestine of the rat in vivo. Gastroenterology 90 (1986) 1972-1977
4. Broccardo M., Improta G., and Tabacco A. Central tachykinin NK3 receptors in the inhibitory action on the rat colonic propulsion of a new tachykinin, PG-KII. Eur J Pharmacol 376 (1999) 67-71
5. Chen C.H., and Rogers R.C. Peptide YY and the Y2 agonist PYY-(13-36) inhibit neurons of the dorsal motor nucleus of the vagus. Am J Physiol 273 (1997) R213-R218
6. Chen C.Y., Chien E.J., Chang F.Y., Lu C.L., Luo J.C., and Lee S.D. Impacts of peripheral obestatin on colonic motility and secretion in conscious fed rats. Peptides 29 (2008) 1603-1608
7. Cox H.M. Peptide YY: a neuroendocrine neighbor of note. Peptides 28 (2007) 345-351
8. Cox H.M., and Tough I.R. Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol 135 (2002) 1505-1512
9. Crowell M.D., Shetzline M.A., Moses P.L., Mawe G.M., and Talley N.J. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs 5 (2004) 55-60
10. Goumain M., Voisin T., Lorinet A.M., Ducroc R., Tsocas A., Roze C., et al. The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning. Mol Pharmacol 60 (2001) 124-134
11. Hansen M.B. Neurohumoral control of gastrointestinal motility. Physiol Res 52 (2003) 1-30
12. Hawkey C.J., and Rampton D.S. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?. Gastroenterology 89 (1985) 1162-1188
13. Hyland N.P., Sjoberg F., Tough I.R., Herzog H., and Cox H.M. Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues. Br J Pharmacol 139 (2003) 863-871
14. Imamura M. Effects of surgical manipulation of the intestine on peptide YY and its physiology. Peptides 23 (2002) 403-407
15. Ishiguchi T., Amano T., Matsubayashi H., Tada H., Fujita M., and Takahashi T. Centrally administered neuropeptide Y delays gastric emptying via Y2 receptors in rats. Am J Physiol Regul Integr Comp Physiol 281 (2001) R1522-R1530
16. Keire D.A., Bowers C.W., Solomon T.E., and Reeve Jr. J.R. Structure and receptor binding of PYY analogs. Peptides 23 (2002) 305-321
17. Koslo R.J., Burks T.F., and Porreca F. Centrally administered bombesin affects gastrointestinal transit and colonic bead expulsion through supraspinal mechanisms. J Pharmacol Exp Ther 238 (1986) 62-67
18. Matsuda K., Maehama T., and Kanazawa K. Strumal carcinoid tumor of the ovary: a case exhibiting severe constipation associated with PYY. Gynecol Oncol 87 (2002) 143-145
19. Miyata K., Ito H., Yamano M., Hidaka K., Kamato T., Nishida A., et al. Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation. Eur J Pharmacol 250 (1993) 303-310
20. Monnikes H., Tebbe J., Bauer C., Grote C., and Arnold R. Neuropeptide Y in the paraventricular nucleus of the hypothalamus stimulates colonic transit by peripheral cholinergic and central CRF pathways. Neurogastroenterol Motil 12 (2000) 343-352
21. Nakade Y., Mantyh C., Pappas T.N., and Takahashi T. Fecal pellet output does not always correlate with colonic transit in response to restraint stress and corticotropin-releasing factor in rats. J Gastroenterol 42 (2007) 279-282
22. Niemegeers C.J.E.A.F., and Janssen P.A.J. The castor oil test in rats: an in vivo method to evaluate antipropulsive and antisecretory activity of antidiarrheals?. Drug Dev Res 4 (1984) 223-227
23. Ozaki A., Yoshidomi M., and Sukamoto T. Effect of the 5-hydroxytryptamine3 (5-HT3)-receptor antagonist KB-R6933 on experimental diarrhea models. Jpn J Pharmacol 80 (1999) 93-96
24. Peterson J.W., and Ochoa L.G. Role of prostaglandins and cAMP in the secretory effects of cholera toxin. Science 245 (1989) 857-859
25. Pinto L., Izzo A.A., Cascio M.G., Bisogno T., Hospodar-Scott K., Brown D.R., et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123 (2002) 227-234
26. Playford R.J., Domin J., Beacham J., Parmar K.B., Tatemoto K., Bloom S.R., et al. Preliminary report: role of peptide YY in defence against diarrhoea. Lancet 335 (1990) 1555-1557
27. Riviere P.J., Farmer S.C., Burks T.F., and Porreca F. Prostaglandin E2-induced diarrhea in mice: importance of colonic secretion. J Pharmacol Exp Ther 256 (1991) 547-552
28. Roze C., Molis C., Xiaomei F.C., Ropert A., Geneve J., and Galmiche J.P. Peptide YY inhibition of prostaglandin-induced intestinal secretion is haloperidol-sensitive in humans. Gastroenterology 112 (1997) 1520-1528
29. Saito T., Mizutani F., Iwanaga Y., Morikawa K., and Kato H. Laxative and anti-diarrheal activity of polycarbophil in mice and rats. Jpn J Pharmacol 89 (2002) 133-141
30. Shigeta H., Taga M., Kurogi K., Kitamura H., Motoyama T., and Gorai I. Ovarian strumal carcinoid with severe constipation: immunohistochemical and mRNA analyses of peptide YY. Hum Pathol 30 (1999) 242-246
31. Shimizu I., Kawashima K., Yoshida N., and Ito T. Analysis of 16,16-dimethylprostaglandin E2-induced diarrhea in cecectomized rats. Arch Int Pharmacodyn Ther 328 (1994) 326-343
32. Shook J.E., Burks T.F., Wasley J.W., and Norman J.A. Novel calmodulin antagonist CGS 9343B inhibits secretory diarrhea. J Pharmacol Exp Ther 251 (1989) 247-252
33. Smith-White M.A., and Potter E.K. Structure-activity analysis of N-acetyl [Leu(28,31)] NPY 24-36: a potent neuropeptide Y Y(2) receptor agonist. Neuropeptides 33 (1999) 526-533
34. Souli A., Chariot J., Voisin T., Presset O., Tsocas A., Balasubramaniam A., et al. Several receptors mediate the antisecretory effect of peptide YY, neuropeptide Y, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo. Peptides 18 (1997) 551-557
35. Whang E.E., Hines O.J., Reeve Jr. J.R., Grandt D., Moser J.A., Bilchik A.J., et al. Antisecretory mechanisms of peptide YY in rat distal colon. Dig Dis Sci 42 (1997) 1121-1127